Editor's Pick: Markets: The week that was (16-20/11/09)

(SNG.L) Synairgen PLC Buy/Sell

Add to portfolio Set Alert Level 2 Desktop Trader

Summary

Current Market Information

Time: 08:13

Bid	37.00
Ask	38.00
Price	37.50
Previous	39.50
Change	-2.25 (-5.70%)
Last Trade	37.25 (16:30:02)
Trading Vol.	139,761
Today's High	38.98
Today's Low	36.50

52 Wk Low	11.00
52 Wk Low	(04/03/2009)
52 Wk High	66.44
52 Wk High	(12/11/2009)
52 Wk Change	+20.25
52 Wk Change	(+119.12%)
4 Wk Volume	6,143,289
ISIN Number	GB00B0381Z20
Currency	GBX

More Trades Info

Performance Graph
3 month closing prices

More Chart Options

Fundamentals
Operating Profit (m)

More SNG.L Research

Sector Heat Map

1 Month Biggest Movers

More Sector Analysis

Recent News
Date/Time	Headline	Source
12-11-09	Synairgen plc - Successful Outcome of Phase 1 Study	RNS
RNS Number : 3825C Synairgen plc 12 November 2009 Synairgen plc ('Synairgen' or the 'Company') Synairgen announces successful outcome of Phase I safety and antiviral 'proof of mechanism' biomarker study of inhaled interferon beta in asthmatic subjects Southampton, UK - 12 November 2009: Synairgen plc (LSE: SNG), the respiratory company with a particular focus on viral defence in asthma and chronic obstructive pulmonary disease ('COPD'), announces the successful outcome of its second Phase I clinical study (SG004) for inhaled interferon beta ('IFN-beta'), which the Company is developing for the treatment of viral infection in asthma and COPD sufferers. The aims of the study were to assess the safety of inhaled IFN-beta in the target population and to establish that it activates antiviral defences in the lungs of asthmatics. Safety data In SG004, conducted jointly by Synairgen in Southampton and The Medicines Evaluation Unit in Manchester, 40 moderate asthmatics received a range of doses of inhaled IFN-beta or placebo over a period of up to two weeks. Inhaled IFN-beta was well-tolerated, causing no adverse effect on standard measures of lung function and inflammation. "We are pleased that inhaled IFN-* was well tolerated at a dose level that we predict will be efficacious in asthma and COPD", said Prof. Ratko Djukanovic, Synairgen Co-Founder and Director of the Southampton NIHR Respiratory Biomedical Research Unit, who was the Chief Investigator for the study. Antiviral activity Neopterin is a well-recognised marker of IFN-beta antiviral activity. Synairgen has developed and validated a test for measuring neopterin in airway secretions. Analysis of the study samples shows statistically significant and dose dependant increases in neopterin levels indicating that antiviral defences have been activated in the lung. Furthermore there were increases of between 4 fold and 64 fold in the gene expression of three antiviral proteins (MxA, 2-5-OAS and IP-10) in the lung cells of these asthmatic volunteers 24 hours after inhaling IFN-beta. This indicates that inhaled IFN-beta stimulated a broad antiviral response in the lung. Prof. Stephen Holgate, Co-Founder and non-executive director of Synairgen, commented "We are very pleased with the exciting results from this study in moderate asthmatics. The safety data is most reassuring and also to see four markers of the antiviral response greatly increases our confidence ahead of the Phase II efficacy studies due to commence in the spring next year." Ends- For further information, please contact: `Synairgen plc Tel: + 44 (0) 23 8051 2800` Richard Marsden, Chief Executive Officer John Ward, Finance Director `Matrix Corporate Capital LLP Tel: + 44 (0) 20 3206 7000` Alastair Stratton Anu Tayal `Threadneedle Communications Tel: + 44 (0) 20 7653 9850` Graham Herring Josh Royston Notes to editors About Synairgen Synairgen is a drug discovery and development company founded by Professors Stephen Holgate, Donna Davies and Ratko Djukanovic, focused on identifying and out-licensing new pharmaceutical products which address the underlying causes of asthma and COPD. Synairgen is listed on AIM (LSE: SNG). Synairgen's researchers use advanced cell models incorporating human tissue and cells drawn from its biobank of clinical samples, which are obtained from well-characterised healthy control, asthma or COPD volunteers. For more information about Synairgen please see www.synairgen.com. Synairgen's interferon beta ('IFN-beta') programme Synairgen is developing inhaled IFN-beta as a therapy to combat viral-induced asthma and COPD exacerbations. Using in vitro human models, it was discovered that epithelial cells (cells which line the airways) from both subjects with asthma1 and COPD have significantly weaker anti-viral responses to the common cold virus than healthy control subjects. The addition of low levels of IFN-beta into the models restored anti-viral responses (simulating aerosolised IFN-beta therapy). This suggests that local delivery of IFN-beta to the lungs could limit the spread of virus to lungs in subjects with respiratory disease and the consequent worsening of their symptoms. Synairgen has entered into a supply and licence agreement for a patent-protected formulation of IFN-beta from the Rentschler Group in Germany. SG004 SG004, a placebo-controlled Phase I study in controlled asthmatics taking inhaled corticosteroids, used the Company's exclusively in-licensed Rentschler formulation of inhaled IFN-beta and was designed to establish its safety at four different dose regimens, over a period of up to 14 days. In addition, biomarker activity (see below) was measured as an indicator of antiviral activity. The SG004 study was conducted by Synairgen in Southampton and the Medicines Evaluation Unit in Manchester, both sites with renowned expertise in advanced respiratory trials. The first volunteer was entered into the study in July 2008 and the trial was completed in September 2009. Biomarkers Neopterin is a recognised IFN-beta biomarker and has been measured in blood during IFN-beta studies in multiple sclerosis. Synairgen has developed a technique for measuring neopterin in airway secretions (sputum), which reflects antiviral activity locally in the lung. Biomarker levels have been monitored in SG004 to confirm the biological activity of IFN-beta delivered to the lungs. Successful biomarker data further supports the original dosing rationale and helps the Company to set the dose for Phase II. In June 2009, Synairgen raised £6 million to finance two Phase II proof of concept studies of inhaled IFN-beta in asthma and COPD. In August 2009, the patent for inhaled IFN-beta to treat rhinovirus infections in asthma and COPD was granted in the USA. The patent forms part of a patent portfolio owned by the University of Southampton, which is exclusively licensed to Synairgen. `Asthma statistics` THERE ARE APPROXIMATELY 23 MILLION ASTHMATICS IN THE USA2 THE ECONOMIC COST TO THE USA OF ASTHMA IS $19.7 BILLION PER YEAR2 ASTHMA ACCOUNTS FOR 1.7 MILLION EMERGENCY DEPARTMENT VISITS PER YEAR IN THE USA2 THE COST OF EMERGENCY DEPARTMENT VISITS AND IN-PATIENT CARE IN RELATION TO ASTHMA IN THE USA IS $4.7 BILLION2 THE AVERAGE DURATION OF A HOSPITALISATION FOR AN ASTHMA EXACERBATION IN THE USA IS 2.7 DAYS AT A COST OF $9,0783 50% OF THE TOTAL COST OF THE ASTHMA IS APPORTIONED TO 10% OF THE ASTHMATIC POPULATION WITH THE SEVEREST DISEASE4 COPD statistics COPD INCLUDES CHRONIC BRONCHITIS AND EMPHYSEMA COPD IS FORECAST TO BE THE THIRD LEADING CAUSE OF DEATH WORLDWIDE (AFTER HEART ATTACK AND STROKE) BY 20305 12 MILLION ADULTS IN THE USA HAVE REPORTED A PHYSICIAN DIAGNOSIS OF COPD AND IT IS ESTIMATED THAT ANOTHER 12 MILLION MAY HAVE COPD BUT DO NOT REALISE IT6 THE ECONOMIC COST TO THE USA OF COPD IS $42.6 BILLION PER YEAR7 HOSPITAL CARE COST $11.3 BILLION2 AND IN 2006 THERE WERE 672,000 HOSPITALIZATIONS FOR COPD IN THE USA8 Rhinovirus (common cold virus) and exacerbations (worsening of symptoms) of asthma and COPD ADULTS GET AN AVERAGE OF TWO TO FOUR COLDS PER YEAR, MOSTLY BETWEEN SEPTEMBER AND MAY. YOUNG CHILDREN SUFFER FROM AN AVERAGE OF SIX TO EIGHT COLDS PER YEAR9 RHINOVIRUS INFECTIONS ARE THE MAJOR CAUSE OF ASTHMA EXACERBATIONS, ACCOUNTING FOR 50% TO 80% OF ALL SUCH ATTACKS IN BOTH CHILDREN AND ADULTS10 80-85% OF COPD EXACERBATIONS ARE ASSOCIATED WITH VIRAL OR BACTERIAL RESPIRATORY TRACT INFECTIONS WITH RHINOVIRUS AND HAEMOPHILUS INFLUENZAE THOUGHT TO BE THE MAJOR CONTRIBUTORS11 References 1. P. Wark et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med. 2005; 201: 937-947 2. American Lung Association. Trends in Asthma Morbidity and Morality. January 2009 www.lungusa.org 3. V. Krishnan et al. Mortality in patients hospitalized for asthma exacerbations in the United States. Am J Respir Crit Care Med 2006 174, 633-638 4. P.J. Barnes, B. Johnson, J.B. Klim. The Costs of Asthma. Eur Respir J 1996 9, 636-642 5. World Health Organisation website (http://www.who.int/respiratory/copd/burden/en/index.html) 6. US National Heart Lung and Blood Institute website(http://www.nhlbi.nih.gov/health/public/lung/copd/index.htm) 7. National Heart Lung and Blood Institute, Morbidity and Mortality: 2007 Chartbook on Cardiovascular, Lung and Blood Diseases 8. American Lung Association: Trends in COPD (chronic bronchitis and emphysema): Morbidity and Mortality. April 2009 www.lungusa.org 9. American Lung Association: Cold and Flu Guidelines: The Common Cold www.lungusa.org 10. J.T. Kelly et al. Host immune responses to rhinovirus: Mechanisms in asthma. J Allergy Clin Immunol 2008; 122: 671-682 11. A. Sethi et al. Infection in the Pathogenesis and Course of Chronic Obstructive Pulmonary Disease. N Engl J Med 2008; 359: 2355-65 This information is provided by RNS The company news service from the London Stock Exchange END MSCGUGBGGUPBGBG More
11-11-09	Synairgen plc - Result of AGM	RNS
RNS Number : 3490C Synairgen plc 11 November 2009 Synairgen plc Results of AGM Southampton, UK - 11 November 2009: The Board of Synairgen plc (LSE: SNG) announces that at the Annual General Meeting held today all resolutions proposed were duly passed by shareholders. Ends- For further information, please contact: `Synairgen plc Tel: + 44 (0) 23 8051 2800` Richard Marsden, Chief Executive Officer John Ward, Finance Director `Matrix Corporate Capital LLP Tel: + 44 (0) 20 3206 7000` Alastair Stratton Anu Tayal `Threadneedle Communications Tel: + 44 (0) 20 7653 9850` Josh Royston This information is provided by RNS The company news service from the London Stock Exchange END RAGBXBDBDDBGGCB More
09-11-09	Synairgen plc - activity of interferon beta against swine flu	RNS
RNS Number : 1640C Synairgen plc 09 November 2009 Press release Synairgen plc ('Synairgen' or the 'Company') Synairgen announces in vitro antiviral activity of interferon beta against 2009 H1N1 ('swine flu') Southampton, UK - 9 November 2009: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company with a particular focus on viral defence in asthma and chronic obstructive pulmonary disease ('COPD'), announces that, as part of its development programme for inhaled interferon beta ('IFN-beta') in asthma and COPD, laboratory experiments have been completed which confirm the antiviral potency of IFN-beta against 2009 H1N1. In the experiments, performed for Synairgen by the Health Protection Agency's Centre for Emergency Preparedness and Response (Porton Down, Salisbury), lung cells were grown in cell culture. These cells were then exposed to the 2009 H1N1 (Strain: Influenza A/California/04/2009(H1N1)), resulting in around 70% of cells becoming infected. In the presence of IFN-beta, the proportion of cells infected with the virus was reduced by at least 94% over 3 experiments. This suggests that IFN-beta may have the potential to prevent H1N1-induced respiratory exacerbations of asthma and COPD. Inhaled IFN-beta is being developed by Synairgen to prevent respiratory viruses spreading from the nose and throat to the lungs, where the exacerbations of asthma and COPD patients occur. On the basis of these promising H1N1 data, Synairgen is evaluating the further potential of this therapy. Professor Stephen Holgate, Co-founder and non-executive director of Synairgen, commented, "This shows how broad an antiviral therapy interferon beta could be. The key point is that interferon beta acts by protecting the host cells rather than targeting any one incoming specific virus, which is the strategy of other therapies in development. 28% of patients admitted to hospital in the USA with 2009 H1N1 have been asthmatics. These exacerbation-prone patients need the kind of protection that interferon beta might provide. " Richard Marsden, Chief Executive Officer, commented, "This is very exciting news for our inhaled interferon beta programme. In our asthma Phase II trial we intend to treat patients with inhaled interferon beta who have developed respiratory virus symptoms. Having already shown interferon beta activity against the main common cold viruses, rhinovirus and respiratory syncytial virus (RSV), we can now add H1N1 to our existing body of evidence, and will be continuing further experiments with other flu viruses." Professor Stephen Holgate and Richard Marsden will comment further on this announcement at the Synairgen Investor Conference on Thursday 12 November. Contact Threadneedle Communications for more information. Ends- `For further information, please contact:` `Synairgen plc Tel: + 44 (0) 23 8051 2800` Richard Marsden, Chief Executive Officer John Ward, Finance Director `Matrix Corporate Capital LLP Tel: + 44 (0) 20 3206 7000` Alastair Stratton Anu Tayal `Threadneedle Communications Tel: + 44 (0) 20 7653 9850` Graham Herring Josh Royston `Notes to editors` About Synairgen Synairgen is a drug discovery and development company founded by Professors Stephen Holgate, Donna Davies and Ratko Djukanovic, focused on identifying and out-licensing new pharmaceutical products which address the underlying causes of asthma and COPD. Synairgen is listed on AIM (LSE: SNG). Synairgen's researchers use advanced cell models incorporating human tissue and cells drawn from its biobank of clinical samples, which are obtained from well-characterised healthy control, asthma or COPD volunteers. For more information about Synairgen please see www.synairgen.com. Synairgen's interferon beta ('IFN-beta') programme Synairgen is developing inhaled IFN-beta as a therapy to combat viral-induced asthma and COPD exacerbations. Using in vitro human models, it was discovered that epithelial cells (cells which line the airways) from both subjects with asthma1 and COPD have significantly weaker antiviral responses to the common cold virus than healthy control subjects. The addition of low levels of IFN-beta into the models restored antiviral responses (simulating aerosolised IFN-beta therapy). This suggests that local delivery of IFN-beta to the lungs could limit the spread of virus to lungs in subjects with respiratory disease and the consequent worsening of their symptoms. Synairgen has entered into a supply and licence agreement for a patent-protected formulation of IFN-beta from the Rentschler Group in Germany. SG004 SG004, a placebo-controlled Phase I study in controlled asthmatics taking inhaled corticosteroids, used the Company's exclusively in-licensed Rentschler formulation of inhaled IFN-beta and was designed to establish its safety at four different dose levels over a 14 day period. In addition biomarker activity (see below) is being measured as an indicator of antiviral activity. The SG004 study has been conducted by Synairgen in Southampton and the Medicines Evaluation Unit in Manchester, both sites with renowned expertise in advanced respiratory trials. The first volunteer was entered into the study in July 2008 and the trial was completed in September 2009. Biomarkers Neopterin is a recognised IFN-beta biomarker and has been measured in blood during IFN-beta studies in multiple sclerosis. Synairgen has developed a technique for measuring neopterin in sputum, which reflects antiviral activity locally in the lung. Biomarker levels have been monitored in SG004 to confirm the biological activity of IFN-beta delivered to the lungs. Successful biomarker data will further support the original dosing rationale and help the Company set the dose for Phase II. SG004 results Synairgen will be announcing the safety and biomarker results of SG004 on 12 November 2009. Synairgen raised £6 million to finance two Phase II proof of concept studies of inhaled IFN-beta in asthma and COPD. In August 2009, the patent for inhaled IFN-beta to treat rhinovirus infections in asthma and COPD was granted in the USA. The patent forms part of a patent portfolio owned by the University of Southampton, which is exclusively licensed to Synairgen. `Asthma statistics` THERE ARE APPROXIMATELY 23 MILLION ASTHMATICS IN THE USA2 THE ECONOMIC COST TO THE USA OF ASTHMA IS $19.7 BILLION PER YEAR2 ASTHMA ACCOUNTS FOR 1.7 MILLION EMERGENCY DEPARTMENT VISITS PER YEAR IN THE USA2 THE COST OF EMERGENCY DEPARTMENT VISITS AND IN-PATIENT CARE IN RELATION TO ASTHMA IN THE USA IS $4.7 BILLION2 THE AVERAGE DURATION OF A HOSPITALISATION FOR AN ASTHMA EXACERBATION IN THE USA IS 2.7 DAYS AT A COST OF $9,0783 50% OF THE TOTAL COST OF THE ASTHMA IS APPORTIONED TO 10% OF THE ASTHMATIC POPULATION WITH THE SEVEREST DISEASE4 COPD statistics COPD INCLUDES CHRONIC BRONCHITIS AND EMPHYSEMA COPD IS FORECAST TO BE THE THIRD LEADING CAUSE OF DEATH WORLDWIDE (AFTER HEART ATTACK AND STROKE) BY 20305 12 MILLION ADULTS IN THE USA HAVE REPORTED A PHYSICIAN DIAGNOSIS OF COPD AND IT IS ESTIMATED THAT ANOTHER 12 MILLION MAY HAVE COPD BUT DO NOT REALISE IT6 THE ECONOMIC COST TO THE USA OF COPD IS $42.6 BILLION PER YEAR7 HOSPITAL CARE COST $11.3 BILLION2 AND IN 2006 THERE WERE 672,000 HOSPITALIZATIONS FOR COPD IN THE USA8 Rhinovirus (common cold virus) and exacerbations (worsening of symptoms) of asthma and COPD ADULTS GET AN AVERAGE OF TWO TO FOUR COLDS PER YEAR, MOSTLY BETWEEN SEPTEMBER AND MAY. YOUNG CHILDREN SUFFER FROM AN AVERAGE OF SIX TO EIGHT COLDS PER YEAR9 RHINOVIRUS INFECTIONS ARE THE MAJOR CAUSE OF ASTHMA EXACERBATIONS, ACCOUNTING FOR 50% TO 80% OF ALL SUCH ATTACKS IN BOTH CHILDREN AND ADULTS10 80-85% OF COPD EXACERBATIONS ARE ASSOCIATED WITH VIRAL OR BACTERIAL RESPIRATORY TRACT INFECTIONS WITH RHINOVIRUS AND HAEMOPHILUS INFLUENZAE THOUGHT TO BE THE MAJOR CONTRIBUTORS11 H1N1 and asthma Asthma is the most common underlying condition for hospitalised H1N1 patients - In the USA, 28%% of hospitalised 2009 H1N1 flu patients had asthma12 References `1. P. Wark et al.Asthmatic bronchial epithelial cells have a deficient innate immune response to infection` with rhinovirus. J Exp Med. 2005; 201: 937-947 `2. American Lung Association. Trends in Asthma Morbidity and Morality. January 2009 www.lungusa.org` `3. V. Krishnan et al. Mortality in patients hospitalized for asthma exacerbations in the United States. Am J` Respir Crit Care Med 2006 174, 633-638 `4. P.J. Barnes, B. Johnson, J.B. Klim. The Costs of Asthma. Eur Respir J 1996 9, 636-642` `5. World Health Organisation website` (http://www.who.int/respiratory/copd/burden/en/index.html) `6. US National Heart Lung and Blood Institute website` (http://www.nhlbi.nih.gov/health/public/lung/copd/index.htm) `7. National Heart Lung and Blood Institute, Morbidity and Mortality: 2007 Chartbook on Cardiovascular,` Lung and Blood Diseases `8. American Lung Association: Trends in COPD (chronic bronchitis and emphysema): Morbidity and` Mortality. April 2009 www.lungusa.org `9. American Lung Association: Cold and Flu Guidelines: The Common Cold www.lungusa.org` `10. J.T. Kelly et al. Host immune responses to rhinovirus: Mechanisms in asthma. J Allergy Clin Immunol` 2008; 122: 671-682 `11. A. Sethi et al. Infection in the Pathogenesis and Course of Chronic Obstructive Pulmonary Disease. N` Engl J Med 2008; 359: 2355-65 `12. S. Jain et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009.` Published at www.nejm.org 8 October 2009 This information is provided by RNS The company news service from the London Stock Exchange END MSCUUGACGUPBGRR More
26-10-09	Synairgen plc - Notice of Investor Conference	RNS
RNS Number : 3346B Synairgen plc 26 October 2009 Press release Synairgen plc ('Synairgen' or the 'Company') Investor Conference Southampton, UK - 26 October 2009: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company with a particular focus on viral defence in asthma and chronic obstructive pulmonary disease ('COPD'), announces that it will be holding an investor conference on Thursday 12 November 2009. The conference will be hosted by Professor Stephen Holgate who will be discussing emerging therapies in asthma and COPD amongst other matters. The Company will also be announcing the safety and biomarker results of its Phase I study of inhaled interferon beta in asthmatic subjects (SG004). The conference will take place at 10 am. If you are interested in attending, please contact Threadneedle Communications for details. Ends- For further information, please contact: `Synairgen plc Tel: + 44 (0) 23 8051 2800` Richard Marsden, Chief Executive Officer John Ward, Finance Director `Matrix Corporate Capital LLP Tel: + 44 (0) 20 3206 7000` Alastair Stratton Anu Tayal `Threadneedle Communications Tel: + 44 (0) 20 7653 9850` Graham Herring Josh Royston `Notes to editors` About Synairgen Synairgen is a drug discovery and development company founded by Professors Stephen Holgate, Donna Davies and Ratko Djukanovic, focused on identifying and out-licensing new pharmaceutical products which address the underlying causes of asthma and COPD. Synairgen is listed on AIM (LSE: SNG). Synairgen's researchers use advanced cell models incorporating human tissue and cells drawn from its biobank of clinical samples, which are obtained from well-characterised healthy control, asthma or COPD volunteers. For more information about Synairgen please see www.synairgen.com. Synairgen's interferon beta ('IFN-beta') programme Synairgen is developing inhaled IFN-beta as a therapy to combat viral-induced asthma and COPD exacerbations. Using in vitro human models, it was discovered that epithelial cells (cells which line the airways) from both subjects with asthma1 and COPD have significantly weaker anti-viral responses to the common cold virus than healthy control subjects. The addition of low levels of IFN-beta into the models restored anti-viral responses (simulating aerosolised IFN-beta therapy). This suggests that local delivery of IFN-beta to the lungs could limit the spread of virus to lungs in subjects with respiratory disease and the consequent worsening of their symptoms. Synairgen has entered into a supply and licence agreement for a patent-protected formulation of IFN-beta from the Rentschler Group in Germany. SG004 SG004, a placebo-controlled Phase I study in controlled asthmatics taking inhaled corticosteroids, used the Company's exclusively in-licensed Rentschler formulation of inhaled IFN-beta and was designed to establish its safety at four different dose levels over a 14 day period. In addition biomarker activity (see below) is being measured as an indicator of antiviral activity. The SG004 study has been conducted by Synairgen in Southampton and the Medicines Evaluation Unit in Manchester, both sites with renowned expertise in advanced respiratory trials. The first volunteer was entered into the study in July 2008 and the trial was completed in September 2009. Biomarkers Neopterin is a recognised IFN-beta biomarker and has been measured in blood during IFN-beta studies in multiple sclerosis. Synairgen has developed a technique for measuring neopterin in sputum, which reflects antiviral activity locally in the lung. Biomarker levels have been monitored in SG004 to confirm the biological activity of IFN-beta delivered to the lungs. Successful biomarker data will further support the original dosing rationale and help the Company set the dose for Phase II. In June 2009, Synairgen raised £6 million to finance two Phase II proof of concept studies of inhaled IFN-beta in asthma and COPD. In August 2009, the patent for inhaled IFN-beta to treat rhinovirus infections in asthma and COPD was granted in the USA. The patent forms part of a patent portfolio owned by the University of Southampton, which is exclusively licensed to Synairgen. `Asthma statistics` THERE ARE APPROXIMATELY 23 MILLION ASTHMATICS IN THE USA2 THE ECONOMIC COST TO THE USA OF ASTHMA IS $19.7 BILLION PER YEAR2 ASTHMA ACCOUNTS FOR 1.7 MILLION EMERGENCY DEPARTMENT VISITS PER YEAR IN THE USA2 THE COST OF EMERGENCY DEPARTMENT VISITS AND IN-PATIENT CARE IN RELATION TO ASTHMA IN THE USA IS $4.7 BILLION2 THE AVERAGE DURATION OF A HOSPITALISATION FOR AN ASTHMA EXACERBATION IN THE USA IS 2.7 DAYS AT A COST OF $9,0783 50% OF THE TOTAL COST OF THE ASTHMA IS APPORTIONED TO 10% OF THE ASTHMATIC POPULATION WITH THE SEVEREST DISEASE4 COPD statistics COPD INCLUDES CHRONIC BRONCHITIS AND EMPHYSEMA COPD IS FORECAST TO BE THE THIRD LEADING CAUSE OF DEATH WORLDWIDE (AFTER HEART ATTACK AND STROKE) BY 20305 12 MILLION ADULTS IN THE USA HAVE REPORTED A PHYSICIAN DIAGNOSIS OF COPD AND IT IS ESTIMATED THAT ANOTHER 12 MILLION MAY HAVE COPD BUT DO NOT REALISE IT6 THE ECONOMIC COST TO THE USA OF COPD IS $42.6 BILLION PER YEAR7 HOSPITAL CARE COST $11.3 BILLION2 AND IN 2006 THERE WERE 672,000 HOSPITALIZATIONS FOR COPD IN THE USA8 Rhinovirus (common cold virus) and exacerbations (worsening of symptoms) of asthma and COPD ADULTS GET AN AVERAGE OF TWO TO FOUR COLDS PER YEAR, MOSTLY BETWEEN SEPTEMBER AND MAY. YOUNG CHILDREN SUFFER FROM AN AVERAGE OF SIX TO EIGHT COLDS PER YEAR9 RHINOVIRUS INFECTIONS ARE THE MAJOR CAUSE OF ASTHMA EXACERBATIONS, ACCOUNTING FOR 50% TO 80% OF ALL SUCH ATTACKS IN BOTH CHILDREN AND ADULTS10 80-85% OF COPD EXACERBATIONS ARE ASSOCIATED WITH VIRAL OR BACTERIAL RESPIRATORY TRACT INFECTIONS WITH RHINOVIRUS AND HAEMOPHILUS INFLUENZAE THOUGHT TO BE THE MAJOR CONTRIBUTORS11 References 1. P. Wark et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med. 2005; 201: 937-947 2. American Lung Association. Trends in Asthma Morbidity and Morality. January 2009 www.lungusa.org 3. V. Krishnan et al. Mortality in patients hospitalized for asthma exacerbations in the United States. Am J Respir Crit Care Med 2006 174, 633-638 4. P.J. Barnes, B. Johnson, J.B. Klim. The Costs of Asthma. Eur Respir J 1996 9, 636-642 5. World Health Organisation website (http://www.who.int/respiratory/copd/burden/en/index.html) 6. US National Heart Lung and Blood Institute website(http://www.nhlbi.nih.gov/health/public/lung/copd/index.htm) 7. National Heart Lung and Blood Institute, Morbidity and Mortality: 2007 Chartbook on Cardiovascular, Lung and Blood Diseases 8. American Lung Association: Trends in COPD (chronic bronchitis and emphysema): Morbidity and Mortality. April 2009 www.lungusa.org 9. American Lung Association: Cold and Flu Guidelines: The Common Cold www.lungusa.org 10. J.T. Kelly et al. Host immune responses to rhinovirus: Mechanisms in asthma. J Allergy Clin Immunol 2008; 122: 671-682 11. A. Sethi et al. Infection in the Pathogenesis and Course of Chronic Obstructive Pulmonary Disease. N Engl J Med 2008; 359: 2355-65 This information is provided by RNS The company news service from the London Stock Exchange END MSCCKNKNABDDBKB More

More...

1 to 4 of 48 Messages

Post New Message
Date/Time	Subject	Author
Tue 13:35	charts still look strong	crayz1


	View Author's profile \| Add to favourites \| Ignore \| Author's posts
	http://quote.barchart.com/texpert.asp?sym=sng.LS&code=BSTK More \| View thread (1) \| Respond \| Login to Vote up \| Login to Vote down
12-11-09	Grant of options	the wee elf


	View Author's profile \| Add to favourites \| Ignore \| Author's posts
	8 September 2009 Synairgen plc ('Synairgen' or the 'Company') Grant of options On 7 September 2009 Richard Marsden, Chief Executive Officer of Synairgen, was granted options over 605,000 ordinary shares of 1 pence each ("Ordinary Shares") in the Company under the Company's Long-Term Incentive Plan (the "LTIP") at an exercise price of 1 pence per share. Mr Marsden's holding in options over Ordinary Shares has therefore increased to 1,670,459 representing approximately 2.80 per cent. of the issued ordinary share capital of the Company. On 7 September 2009 John Ward, Finance Director of Synairgen, was granted options over 550,000 Ordinary Shares in the Company under the Company's LTIP at an exercise price of 1 pence per share. Mr Ward's holding in options over Ordinary Shares has therefore increased to 1,226,532, representing approximately 2.05 per cent. of the issued ordinary share capital of the Company. On 7 September 2009 Dr Phillip Monk, Chief Scientific Officer of Synairgen, was granted options over 414,625 Ordinary Shares in the Company under the Company's LTIP at an exercise price of 1 pence per share. Dr Monk's holding in options over Ordinary Shares has therefore increased to 554,064, representing approximately 0.93 per cent. of the issued ordinary share capital of the Company. On 7 September 2009 Paul Clegg, Non-executive Director of Synairgen, was granted options over 250,000 Ordinary Shares in the Company under the Synairgen Qualifying Non-Employee Share Option Plan 2009 at an exercise price of 20 pence per share, representing approximately 0.42 per cent. of the issued ordinary share capital of the Company. More \| View thread (1) \| Respond \| Login to Vote up \| Login to Vote down
12-11-09	Re: Share tips Beware	Priestman


	View Author's profile \| Add to favourites \| Ignore \| Author's posts
	I suspect you are spot on with your anaysis of how long this will take and any upside is already factored in. The steep decline caught me out and I wished I had read your earlier post before buying (and subsequently selling because it hit my stop loss and some!) More \| View thread (13) \| Respond \| Login to Vote up \| Login to Vote down
12-11-09	Re: Share tips Beware	the wee elf


	View Author's profile \| Add to favourites \| Ignore \| Author's posts
	But thats were the trouble starts,by relying on others to do the research for you.You seem to have left out,that he also had a buy at 25.75p upto 29p,but then again £1.00 in a year sounds better.I think that if you check your facts,you will find that this was not tipped before the close on Friday by kw. And have just noticed the fall in todays price,so just hope the one's that have bailled out,got out in profit.I also agree with Pharmaguy figures,and if you want confimation on this then have a look at, agy(same sector)and their share price as when the breaking news was announced,and where they are now still waiting for fda approval which may,or may not be granted. Best of luck to all. TWE More \| View thread (13) \| Respond \| Login to Vote up \| Login to Vote down

The contents of the postings summarised here represents the opinions of the authors and not of Interactive Investor Trading Limited.
They have not been approved or issued by Interactive Investor Trading Limited.

Discussion Board Terms & Conditions FSA Market Abuse Fact Sheet

More...